Alpha 2.0
Login Register
» Articles » PMID: 32797372

Satralizumab: First Approval

Overview
Journal Drugs
Specialty Pharmacology
Date 2020 Aug 16
PMID 32797372
Citations 26
Authors
Young-A Heo
Affiliations
Soon will be listed here.
Abstract

Satralizumab (Enspryng), a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody, has been developed by Chugai Pharmaceutical and Roche for the treatment of neuromyelitis optica spectrum disorder (NMOSD). In June 2020, based on positive results from two pivotal phase III trials, subcutaneous satralizumab received its first global approval in Canada for the treatment of NMOSD in adults and children aged ≥ 12 years who are aquaporin 4 water channel autoantibody (AQP4-IgG) seropositive. Satralizumab was subsequently approved in Japan, Switzerland and the USA. Satralizumab is under regulatory review in the EU, and is undergoing clinical development in several countries worldwide. This article summarizes the milestones in the development of satralizumab leading to this first approval for the treatment of NMOSD.

Citing Articles

New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.

Nada H, Choi Y, Kim S, Jeong K, Meanwell N, Lee K Signal Transduct Target Ther. 2024; 9(1):341.

PMID: 39638817 PMC: 11621763. DOI: 10.1038/s41392-024-02036-3.

Targeted Treatments for Myasthenia Gravis in Children and Adolescents.

Ramdas S, Painho T, Vanegas M, Famili D, Lim M, Jungbluth H Paediatr Drugs. 2024; 26(6):719-740.

PMID: 39198371 DOI: 10.1007/s40272-024-00649-3.

Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.

Devanaboyina S, Li P, LaGory E, Poon-Andersen C, Cook K, Soto M MAbs. 2024; 16(1):2383013.

PMID: 39051531 PMC: 11275528. DOI: 10.1080/19420862.2024.2383013.

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance.

Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M Neurol Ther. 2024; 13(5):1361-1383.

PMID: 39012406 PMC: 11393251. DOI: 10.1007/s40120-024-00640-7.

New advancements in the management of Neuromyelitis Optica spectrum disease: literature review.

Sudhakar P, Abusamra K, Thandampallayam M, Kini A Front Ophthalmol (Lausanne). 2024; 3:1130971.

PMID: 38982999 PMC: 11182166. DOI: 10.3389/fopht.2023.1130971.

References
1.
Xue T, Yang Y, Lu Q, Gao B, Chen Z, Wang Z . Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials. Mult Scler Relat Disord. 2020; 43:102166. DOI: 10.1016/j.msard.2020.102166. View
2.
Yoshizaki K, Nakagawa T, Fukunaga K, Tseng L, Yamamura Y, Kishimoto T . Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol. 1984; 132(6):2948-54. View